Table 1 Patient characteristics according to systemic rheumatic disease
Variable | SLE (N = 15,961) | PM/DM (N = 2270) | SSc (N = 2071) | RA (N = 38,355) | pSS (N = 18,309) |
|---|---|---|---|---|---|
Sex, n (%) | |||||
 Male | 2027 (12.7) | 760 (33.5) | 544 (26.3) | 9013 (23.5) | 2032 (11.1) |
 Female | 13,934 (87.3) | 1510 (66.5) | 1527 (73.7) | 29,342 (76.5) | 16,277 (88.9) |
Age in years, mean ± SD | 37.2 ± 17.0 | 47.8 ± 17.7 | 51.8 ± 15.3 | 53.3 ± 15.4 | 54.7 ± 14.3 |
Age group, n (%) | |||||
 0–16 years | 1342 (8.4) | 148 (6.5) | 32 (1.6) | 712 (1.8) | 42 (0.2) |
 16–45 years | 9853 (61.7) | 767 (33.8) | 610 (29.4) | 9688 (25.3) | 4363 (23.8) |
 45–65 years | 3512 (22.1) | 975 (43.0) | 1000 (48.3) | 19,105 (49.8) | 9456 (51.6) |
 > 65 years | 1254 (7.8) | 380 (16.7) | 429 (20.7) | 8850 (23.1) | 4448 (24.4) |
Income in NTD, n (%) | |||||
 Low (< 19,200) | 8092 (50.7) | 1270 (56.0) | 1129 (54.5) | 20,647 (53.8) | 9521 (52.0) |
 Intermediate (19,201–40,000) | 6071 (38.1) | 747 (32.9) | 721 (34.8) | 14,024 (36.5) | 6526 (35.6) |
 High (> 40,000) | 1798 (11.2) | 253 (11.1) | 221 (10.7) | 3684 (9.7) | 2262 (12.4) |
Comorbidities, n (%) | |||||
 Diabetes mellitus | 807 (5.1) | 255 (11.3) | 226 (11.0) | 4528 (11.8) | 2116 (11.5) |
 Hypertension | 2574 (16.1) | 536 (23.6) | 556 (26.8) | 10,485 (27.3) | 5277 (28.8) |
 Chronic kidney disease | 1390 (8.7) | 99 (4.4) | 147 (7.1) | 1839 (4.8) | 1064 (5.8) |
 COPD | 862 (5.4) | 240 (10.6) | 273 (13.2) | 3930 (10.3) | 2218 (12.1) |
 Ischaemic heart disease | 971 (6.1) | 264 (11.6) | 282 (13.6) | 4643 (12.1) | 2892 (15.9) |
 Dyslipidaemia | 1202 (7.5) | 381 (16.8) | 315 (15.3) | 5743 (14.9) | 3634 (19.8) |
 CHF | 541 (3.4) | 105 (4.6) | 147 (7.1) | 1303 (3.4) | 584 (3.2) |
 Liver cirrhosis | 270 (1.69) | 37 (1.6) | 58 (2.8) | 444 (1.1) | 401 (2.2) |
 Cerebrovascular disease | 7.3 (4.4) | 101 (4.5) | 126 (6.1) | 2235 (5.8) | 1658 (9.1) |
 Cancer | 739 (4.6) | 279 (12.3) | 128 (6.2) | 2116 (5.5) | 1567 (8.5) |
 Peripheral artery disease | 942 (5.9) | 140 (6.2) | 624 (30.1) | 1314 (3.4) | 1145 (6.25) |
 HBV infection | 317 (2.0) | 113 (4.9) | 46 (2.2) | 1118 (2.9) | 727 (3.9) |
 HCV infection | 249 (1.6) | 54 (2.4) | 39 (1.9) | 877 (2.3) | 705 (3.8) |
 Depression | 735 (4.6) | 109 (4.8) | 110 (5.3) | 2265 (5.9) | 2262 (12.3) |
 Dementia | 92 (0.6) | 13 (0.6) | 12 (0.6) | 322 (0.8) | 279 (1.5) |
Medications, n (%) | |||||
 Corticosteroid | 13,846 (86.7) | 2146 (94.5) | 1442 (69.6) | 29,284 (76.3) | 8912 (48.7) |
 Cyclophosphamide | 1320 (8.3) | 208 (9.2) | 186 (9.0) | 192 (0.5) | 229 (1.25) |
 Methotrexate | 626 (3.9) | 668 (29.4) | 155 (7.5) | 21,310 (55.6) | 829 (4.5) |
 Azathioprine | 3965 (24.8) | 708 (31.2) | 166 (8.0) | 621 (1.6) | 1104 (6.0) |
 Cyclosporine | 270 (1.7) | 99 (4.4) | 37 (1.8) | 1105 (2.9) | 104 (0.57) |
 Leflunomide | 35 (0.21) | 15 (0.7) | 11 (0.5) | 1914 (5.0) | 108 (0.59) |
Length of follow-up (years), mean ± SD | 5.6 ± 4.2 | 4.5 ± 4.1 | 5.3 ± 4.0 | 5.9 ± 3.9 | 4.5 ± 3.5 |